Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus ≥10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial

BACKGROUND: Several studies have shown that darbepoetin alfa, an erythropoiesis-stimulating agent (ESA), can reduce transfusions and increase hemoglobin (Hb) levels in patients with chemotherapy-induced anemia (CIA). Recent safety concerns, however, have prompted changes to ESA product information....

Descripción completa

Detalles Bibliográficos
Autores principales: Vansteenkiste, Johan, Hedenus, Michael, Gascon, Pere, Bokemeyer, Carsten, Ludwig, Heinz, Vermorken, Jan, Hamilton, Lisa, Bridges, Ken, Pujol, Beatriz
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2744706/
https://www.ncbi.nlm.nih.gov/pubmed/19728887
http://dx.doi.org/10.1186/1471-2407-9-311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2744706/
https://www.ncbi.nlm.nih.gov/pubmed/19728887
http://dx.doi.org/10.1186/1471-2407-9-311

Ejemplares similares